Warning Letter: Diversified Manufacturing
ePT--the Electronic Newsletter of Pharmaceutical Technology
This week, the US Food and Drug Administration posted an Oct. 20 Warning Letter (http://www.fda.gov/foi/warning_letters/g5567d.htm) sent by its Minneapolis, MN district office to Diversified Manufacturing Corporation (Newport, MN).
This week, the US Food and Drug Administration posted an Oct. 20 Warning Letter (www.fda.gov/foi/warning_letters/g5567d.htm) sent by its Minneapolis (MN) district office to Diversified Manufacturing Corporation (Newport, MN).
The two-page letter cited shortcomings in the company's manufacture of over-the-counter human drugs, including cited failures to validate equipment cleaning and maintain cleaning and maintenance records, especially for mixing vessels used for multiple products. The agency complained that the company did not have quality laboratory confirmation of conformance to specifications before the drug was released. The agency also found failures to investigate out of specification products.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
